Bio-imaging Technologies Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Bio-imaging Technologies Market Trends and Insights

Growing Need for High-Resolution Biological Imaging in Early Disease Detection

Early cancer detection and neurodegenerative disease screening are changing what buyers expect from imaging systems. Hospitals increasingly seek sub-millimeter resolution and volumetric tissue characterization for routine clinical decisions. GE HealthCare^{[1]GE HealthCare, “AIR Recon DL MR Image Reconstruction,” GE HealthCare, gehealthcare.com}stated that AIR Recon DL had been used in more than 80 million patient scans by mid-2025 and could reduce scan times by up to 50%.

Faster MRI examinations can improve scanner throughput, although they shift more pressure to image reporting and interpretation capacity. Photon-counting CT also offers tissue information that conventional CT cannot provide, supporting earlier assessment of lesions. In neurology and oncology, the use of 7T MRI and PET-MRI supports broader demand for high-resolution and multimodal imaging.

Rising AI-Enabled Image Reconstruction and Quantitative Analysis

The bio-imaging technologies market is seeing AI reconstruction shift competition from detector hardware toward software performance and clinical workflow value. Siemens Healthineers reported that Deep Resolve supported an MRI scan-time reduction of more than 20% at NHS Fife, which created capacity for 1,900 additional appointments in 6 months. Philips^{[2]Philips, “Philips Receives FDA 510(k) Clearance for Verida,” Philips Press Room, philips.com}received FDA 510(k) clearance for Verida, a detector-based spectral CT system that uses an AI reconstruction engine. Philips stated that the system reconstructs 145 images per second and can support up to 270 examinations daily. Software updates can improve the performance of legacy scanner fleets without a capital replacement. This reduces barriers to adoption for hospitals while increasing the importance of software integration and procurement standards.

Expanding Biopharma Use in Drug Discovery, Companion Diagnostics, and Translational Research

The bio-imaging technologies market is also supported as biopharma companies use imaging biomarkers earlier in drug development to improve patient selection and trial decisions. Revvity^{[3]Revvity, “Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis,” BusinessWire, businesswire.com}introduced Living Image Synergy AI in September 2025 for multimodal in vivo analysis across optical imaging, microCT, and ultrasound. The platform addresses reproducibility and data consistency issues in translational research. GE HealthCare completed its acquisition of Nihon Medi-Physics in March 2025, adding a Japanese SPECT and PET radiopharmaceutical supplier to its imaging portfolio. This transaction shows how imaging equipment suppliers are pursuing revenue from agents used in companion diagnostics. Research on transgenic reporter systems also supports the use of PET and bioluminescent imaging together in tumor models.

Procurement Shift toward Portable, Cloud-Connected, and Workflow-Integrated Imaging Platforms

The bio-imaging technologies market is affected as health systems reassess the operating costs of locally managed imaging infrastructure. Emory Healthcare completed the migration of more than 1.3 million annual imaging examinations to Sectra One Cloud in June 2026^{[4]Sectra, “Sectra’s First US Cloud Migration, Emory Healthcare Boosts Scalability and Security by Moving to Sectra One Cloud,” PR Newswire, prnewswire.com}. The move transfers infrastructure maintenance and upgrades to the vendor and supports common software versions across sites. Philips launched the Alturion ultrasound system in June 2026 with FDA clearance and CE marking for high-volume settings. Portable and connected systems can help facilities use imaging results when specialist resources are limited. Buyers are therefore placing more weight on workflow integration, remote access, and lifecycle costs alongside image quality.

High Capital Cost of Advanced Imaging Systems and Software Upgrades

The bio-imaging technologies market faces a cost barrier because acquiring an advanced imaging platform extends beyond the scanner purchase price. A 1.5T or 3.0T MRI system can start at USD 900,000, while installation, service contracts, and software licenses increase lifecycle expenditure. The input data indicates installation costs of USD 150,000 to USD 500,000 and annual service costs of USD 42,000 to USD 134,000. These costs can delay approvals at community hospitals and diagnostic centers, especially in markets with limited financing. A 2026 study across 46 European countries also identified infrastructure, training, and reimbursement as barriers to equitable cardiovascular MRI access. Refurbished systems can reduce capital outlay by 30% to 60%, but buyers must weigh those savings against software compatibility and warranty limitations.

Reimbursement Pressure, Validation Requirements, and Workforce Constraints

The bio-imaging technologies market also faces a reimbursement challenge because regulatory clearance does not automatically result in a clear reimbursement pathway for AI-enabled imaging workflows. CMS and FDA announced the RAPID coverage pathway in April 2026, which may provide national Medicare coverage for eligible Breakthrough Devices as early as 2 months after authorization. The pathway is selective and does not resolve bundled payment limits for most imaging tools. Coverage decisions also require evidence of clinical outcomes, not only better image quality, which can slow implementation. Hospitals need interoperable connections across scanners, AI models, and laboratory information systems to realize workflow benefits. Shortfalls in imaging scientists, AI-trained radiology staff, and advanced application specialists further limit adoption, especially outside major urban care systems.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Technology Type: Molecular Bio-Imaging Expands within a Clinical-Led Base

Medical Bio-Imaging held 62.34% of the revenue share in 2025, reflecting its central role in hospital radiology, diagnostic imaging centers, and emergency care. Its position rests on established clinical workflows and regulated modalities used in everyday diagnostic decisions. 

Molecular Bio-Imaging is projected to record the highest growth at a 10.56% CAGR through 2031. The segment benefits from theranostics, where an imaging agent is linked to a therapeutic radiopharmaceutical for patient selection and treatment monitoring. Lantheus received FDA approval for PYLARIFY TruVu in 2026, a reformulated PSMA PET imaging agent that is intended to improve manufacturing efficiency and supply flexibility.

By Modality: MRI Leads Revenue while Nuclear Imaging Grows Faster

Within the bio-imaging technologies market, Magnetic Resonance Imaging held 22.36% of the bio-imaging technologies market size in 2025. MRI remains important in soft-tissue oncology, neurological assessment, cardiology, and clinical pathways where avoiding ionizing radiation has value. Nuclear Imaging is forecast to grow at a 9.54% CAGR through 2031. 

The segment is supported by radiopharmaceutical approvals, theranostic care models, and broader clinical use in oncology and neurology. Lantheus received FDA tentative approval for PNT2003 in March 2026, a radioequivalent to Lutetium Lu 177 Dotatate for gastroenteropancreatic neuroendocrine tumors. The approval points to a generic pathway that could broaden access to radioligand procedures.

By Application: Oncology Combines Leading Scale and Growth

The oncology segment accounted for 31.24% of the revenue share in 2025 and is forecast to expand at a 9.34% CAGR through 2031. It is the only application in the supplied data that combined the largest revenue share with the fastest projected growth. Imaging is used across therapy planning, patient stratification for targeted treatment, and response monitoring. A 2026 study on glioma classification found that combining radiology and pathology foundation models outperformed unimodal approaches. This supports the procurement of integrated imaging platforms at oncology centers. The application base is therefore tied to both existing diagnostic volume and new precision treatment pathways. Orthopedics, gastroenterology, and infectious disease research form the remaining application base. In May 2026, Japan’s AI Medical Service received approval for gastroAI model-G3 for early gastric cancer and adenoma detection.

By End User: Hospitals Lead Demand while Biopharma Spending Rises

Within the bio-imaging technologies market, Hospitals and Clinics held 46.54% of end-user demand in 2025. Their leading position reflects imaging use across inpatient, outpatient, and emergency care. GE HealthCare and Catholic Health entered a 10-year Care Alliance covering more than 1,300 technology deployments across 40 hospitals and outpatient sites. The agreement carried a value of USD 500 million in the supplied information. Large health systems use these arrangements to update equipment, standardize operations, and support service continuity. Hospitals will remain the central purchaser group because they manage the broadest range of clinical imaging procedures.

Pharmaceutical and Biotechnology Companies are projected to grow at a 10.45% CAGR through 2031, the fastest rate among end users. The growth is linked to radioligand therapy development and the need for matched molecular imaging in patient selection and response monitoring.

Geography Analysis

North America held 41.34% of the revenue share in 2025. The region has a large installed base of clinical imaging equipment, major cancer centers using multimodal protocols, and an evolving reimbursement environment. The CMS-FDA RAPID pathway announced in April 2026 may better align regulatory authorization and Medicare coverage for eligible devices. The United States represents the largest share within the region. Canada and Mexico are smaller markets where cloud imaging and teleradiology can extend diagnostic services into underserved areas.

Asia-Pacific is projected to expand at a 10.32% CAGR through 2031, the fastest regional pace in the supplied data. The growth is linked to policy direction, domestic technology investment, and an expanding private diagnostic sector. China’s November 2025 directive called for AI-assisted medical imaging diagnosis in all secondary-level and higher hospitals by 2030.